Cetuximab - Eli Lilly

Drug Profile

Cetuximab - Eli Lilly

Alternative Names: Anti-EGFR monoclonal antibody 225; C 225; ch 225; Erbitux; IMC-C225; LY-2939777

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California System
  • Developer Array BioPharma; Bristol-Myers Squibb; Centre Jean Perrin; Eli Lilly; Merck KGaA; New York University School of Medicine; Novartis; Pierre Fabre; Roche; University Hospital Ghent; University of Heidelberg; University of Michigan Comprehensive Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Head and neck cancer
  • Phase III Non-small cell lung cancer
  • Phase II Bladder cancer; Breast cancer; Gastric cancer; Mesothelioma; Rectal cancer
  • Phase I/II Adenoid-cystic-carcinoma
  • Phase Unknown Oesophageal cancer
  • No development reported Pancreatic cancer; Prostate cancer

Most Recent Events

  • 23 Jun 2018 Updated efficacy and adverse events data from the phase III BEACON CRC in Colorectal cancer released by Array BioPharma
  • 01 Jun 2018 Efficacy data from the phase III FIRE-3 trial in Colorectal cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 01 Jun 2018 Adverse events data from the phase II AVETUX trial in Colorectal cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top